Spruce Bio
Business Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
611 Gateway Blvd Ste 740, South San Fran...Phone Number
(415) 343-5986Website
www.sprucebio.comRevenue
-Stock Symbol
SPRBIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
1
1
1
1
1
About Spruce Bio
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical needs. The company is developing its wholly-owned product candidate, tildacerfont, as a potential first non-steroidal therapy for patients with classic congenital adrenal hyperplasia (CAH), a serious and life-threatening disease with no novel therapies approved for decades. Spruce is also advancing tildacerfont for women affected by a rare form of polycystic ovary syndrome (PCOS) characterized by primary adrenal androgen excess.Explore more
Spruce Bio Org Chart
Get the full picture
Sign in to uncover key details.
SS
Vice President, Clinical Development
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Spruce Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check out if Spruce Bio is spiking on competitors!
Click to see if Spruce Bio had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Spruce Bio has new funding data
Product Launch: Get notified when Spruce Bio launches new products
Spruce Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Spruce Bio recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Spruce Bio
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Spruce Bio has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Spruce Bio as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Spruce Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Spruce Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Spruce Bio.
Spruce Bio financials insights
Gather financial insights about Spruce Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$20M
2020
Series B
$88M
Stock Offering
$90M
2023
Share Placement
$53.6M
2025
Stock/Share Issuance
$50M
Stock/Share Issuance
$50M
2026
Debt
$50M
Spruce Bio Tech Stack
A closer look at the technologies used by Spruce Bio
Most Recent Scoops
Project
Spruce Bio has a monoclonal antibody in its pipeline targeting congenital adrenal hyperplasia (CAH), which binds CRH as a ligand a mechanism validated by the prior FDA approval of crinecerfont (by Neurocrine) for the same indication.
Medical Research, Pharmaceuticals
Project
Spruce Bio has reported that its five-year biomarker data profound heparan sulfate levels in the CSF within the limit of normal at most time points a result not previously achieved by any other therapeutic or ERT for neuropathic MPS.
Medical Research, Pharmaceuticals
Project
Spruce Bio is planning to initiate an expanded access program in the second half of 2026, in partnership with patient foundations, to allow patients to transition from its clinical trial to commercial product upon availability.
Partnership, Product Launch, Clinical Operations
Project
Spruce Bio has reported that Tralesinidase alfa demonstrates systemic efficacy through normalization of liver and spleen sizes, and a favorable safety profile with no meaningful hypersensitivity reactions and no reduction in therapeutic effect size even in patients where neutralizing antibodies were detected.
Medical Research, Pharmaceuticals
Project
Spruce Bio News & Media
Spruce Biosciences (NASDAQ: SPRB) names Adrian Quartel as chief medical officer
Adrian Quartel, M.D., FFPM joins Spruce Biosciences as CMO, bringing 25+ years of pharma experience and leadership in launching six rare disease treatments at BioMarin.Spruce Biosciences (SPRB) Appoints Dale Hooks as CCO and Reports Narrowed $39M 2025 Net Loss
Spruce Biosciences Inc. (NASDAQ:SPRB) is one of the best hot stocks to buy according to analysts. On March 9, Spruce Biosciences appointed Dale Hooks as Chief Commercial Officer to lead the company’s transition toward its next phase of growth. Hooks brings nearly 35 years of biopharmaceutical experience to the role, having overseen 21 new product […]Spruce Biosciences Touts MPS IIIB Data, Targets Q4 BLA Submission at Oppenheimer Conference
Executives from Spruce Biosciences (NASDAQ:SPRB) outlined regulatory plans, clinical data highlights, and commercial considerations for the company’s lead program in Sanfilippo syndrome type B (MPS IIIB) during a fireside chat at Oppenheimer’s 36th Annual Healthcare and Life Sciences Conference. PrHarbour BioMed stake in US drug firm Spruce shows Chinese firms' growing clout, analysts say
Latest example of Chinese drug maker acquiring equity in overseas partner shows they are becoming true development partners, analysts say.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Spruce Bio
Sign Up For FreeTo access detailed company insights
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical needs. The company is developing its wholly-owned product candidate, tildacerfont, as a potential first non-steroidal therapy for patients with classic congenital adrenal... Read More
